Article

GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease

2023-05-15

Abstract excerpt

<h4>Background: </h4> Agonism at the receptor for the glucose-dependent insulinotropic polypeptide (GIPR) is a key component of the novel unimolecular GIPR:GLP-1R co-agonists, which are among the most promising drugs in clinical development for the treatment of obesity and type 2 diabetes. The therapeutic effect of chronic GIPR agonism to treat dyslipidemia and thus to reduce the cardiovascular disease risk indepe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e6c4a5d7-9b0c-56c5-825e-9d7e8fb70b8e
DOI: 10.21203/rs.3.rs-2912233/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic diseaseDOI 10.21203/rs.3.rs-2912233/v1Read

The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive ReviewSemantic proximity Read

Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.Semantic proximity Read

Hepatocyte Rap1a Contributes To Obesity- and Statin-Associated HyperglycemiaSemantic proximity Read

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Semantic proximity Read

Myeloid Gi signaling acts as a weight-independent immunometabolic switch controlling systemic insulin sensitivitySemantic proximity Read

Phenotype-Directed Precision Therapeutics: A Framework for Multi-Agonist Therapy in Obesity, MASH and Cardio-Renal-Metabolic DisordersSemantic proximity Read

Identification and functional assessment of GPCRs across human adipogenesisSemantic proximity Read

The Cardiovascular Physiology of Glucagon-like Peptide-1 Receptor Agonists: From Macro-level Outcomes to Micro-level MechanismsSemantic proximity Read

Rap1 Activation Protects Against Fatty Liver and Non-Alcoholic Steatohepatitis DevelopmentSemantic proximity Read

Evaluating the efficacy of GIPR agonists on non-alcoholic fatty liver disease: A Mediation Mendelian Randomization Study.Semantic proximity Read

G protein-coupled receptors that influence lifespan of human and animal modelsSemantic proximity Read